SALT LAKE CITY — In this Healio Video Perspective from the ARVO meeting, Justis P. Ehlers, MD, shares results from the phase 1 HELIOS study investigating OTX-TKI for the treatment of nonproliferative diabetic retinopathy.
The study examined a single injection of OTX-TKI (axitinib intravitreal implant, Ocular Therapeutix) vs. sham in reducing intraretinal fluid.
“What we found was that throughout the entire year of the study with a single injection, there was sustained reduction in intraretinal fluid compared to sham,” Ehlers said. “Sham predominantly remained stable